Good news for Lilly: Cyramza nabs yet another FDA approval
- The FDA has approved Cyramza (ramucirumab) for the treatment of advanced colorectal cancer. Cyramza is intended to be used on combination with other oncologic treatment agents.
- This is the fourth approval for Cymramza in just over a year.
- The most recent approval is based on data from the RAISE trial, which shows a 15% decreased risk of death in patients with advanced metastatic colorectal cancer treated with Cyramza in combination with FOLFIRI.
Cyramza is a drug that works via antiangiogenesis, or by preventing the formation of new blood vessels, resulting in tumor starvation and oxygen deprivation.
The strength of the RAISE data has led to Cyramza's fourth indication, based on data showing increased median overall survival of 13.3 months in Cyramza-treated patients, compared with 11.7 months in patients treated with FOLFIRI alone.
Cyramza, which comes with a black box warning for increased risk of hemorrhage and gastrointestinal perforation, is already approved in the U.S. for gastric cancer and non-small cell lung cancer (NSCLC).
- Pharma Times Fourth US approval for Lilly's Cyramza